Vivibot was born by Hopelab
Started developing the App & received our first Angel Investors' Funding
Launched the Beta version of our App with 10 community members
Received Patient Centricity Award at the Summit for Clinical Operations Executives
Won the Healthcare Innovation Competition at South by Southwest
First Peer Reviewed Publication: Audacity of Engagement
Audacity of Engagement paper link
Hearing Directly from Young Adults with Cancer on Their Attitudes and Perceptions of Cancer Survivorship and Cancer Survivorship Research
Hit 100,000 interactions on our App by our 2nd anniversary
Won Appy Award just under 1 year from launching our app
Started our first 2 research projects
One project was with Bristol Myers Squibb and the other was with Seagen. Both projects were focused on trust and the patient experience for the young adult cancer community.
Hit 1 million interaction on app
First Global Virtual Cancer Conference (GVCC)
The first GVCC had over 100 exhibitors, sponsors and speakers that interacted with +3,000 cancer patients and caregivers on Gryt's digital platform in a single day!
Gryt Health acquires full rights to Vivibot from Hopelab
Earned our 2nd Patient Centricity Award from Summit for Clinical Operations Executives
Launched the first COVID Advocacy Exchange Session
Now called The Advocacy Exchange, this is the largest cross-disease, cross-cultural advocacy initiative in healthcare.
COVID-related stats: By April 2020, about half of the world's population was under some form of lockdown due to COVID-19, impacting more than 3.9 billion people in more than 90 countries. Although similar disease control measures have been used for hundreds of years, the scale seen in the 2020s is thought to be unprecedented. In terms of its impact on global healthcare, COVID-19 had interrupted or created problems for patients' access to care, new medication development, global advocacy initiatives, and illuminated racial and ethnic health and healthcare disparities.
Now providing patient experience and patient empowerment services to half of the United States' Top 10 pharmaceutical companies and supporting more than 300 advocacy and non-profit organizations to amplify their impact on our global platforms.
Expanded from 10 to 30 employees
Received Project of the Year Award for GVCC 2021 from MedTech.
Presented 3 Research Posters at the American Society for Hematology Conference for partnered publications for the CONNECT Study with Chief Research Officer, Darcy Flora, PhD as the head author on one of the 3 pieces.
Launched Amgen's tarlatamab clinical trial website and recruitment campaign.
Diversity in Oncology 2.0 launches.
Many more achievements and work impact events to share!
